01 - 05 June 2019
Lisbon, Portugal

Industry Programme

Satellite Symposia

 

Sunday, 2 June 2019


Satellite Symposium (SAT)
Uriach
17:30 – 19:00, Hall 8
 Marca Uriach Pantone
Itching for expert insights? Interactive clinical cases to better manage your pruritus and urticaria patients.
Chair: Marcus Maurer, Germany

Introduction and welcome
Speaker: Marcus Maurer, Germany

Introduction to urticaria (CSU) and skin pruritus
Speaker: Marcus Maurer, Germany

Patients itching for relief
Speaker: Ana Giménez-Arnau, Spain
Speaker: Montserrat Álvaro, Spain
Speaker: Zuotao Zhao, China


Panel discussion/ debate
Speaker: Marcus Maurer, Germany 



Satellite Symposium (SAT)
Mylan
17:30 – 19:00, Hall 10
 Mylan
New Data on Adrenalin Delivery: Dismantling Believes in the Treatment of Anaphylaxis
Chair: Margitta Worm, Germany
Chair: Motohiro Ebisawa, Japan


Introduction
Speaker: Margitta Worm, Germany

Adrenalin Delivery: new data
Speaker: Ferdinand Kopietz, Germany

Does Epipen fit to all anaphylactic patients?
Speaker: George du Toit, United Kingdom

Need for 2 AAIs - Unaccomplished EMA recommendation
Speaker: Antonella Muraro, Italy

Conclusion
Speaker: Motohiro Ebisawa, Japan

Q&A session - All


Satellite Symposium (SAT)
Takeda Pharmaceuticals
17:30 – 19:00, Hall 9
 
Lanadelumab, a First-of-Its-Kind Prevention Treatment in Hereditary Angiodema (HAE)

Learning objectives: Leading international HAE experts will lead a symposium to review the clinical data for lanadelumab*, which was approved by the European Commission in 2018. The audience will learn about the burden and unpredictability of the disease and the opportunity to redefine HAE prevention with lanadelumab. The speakers will present the clinical efficacy data, dosing and safety profile, as observed in the phase 3 HELP study. The symposium will incorporate both real-world experiences and supporting clinical data to introduce lanadelumab as a first-of-its-kind preventive treatment for HAE.
*lanadelumab is a fully human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

Introductions

Understanding the Burden of HAE
Speaker: Markus Magerl, Germany

Clinical Data from the HELP Study
Speaker: Aleena Banerji, United States

Beyond the Data: Key Features of Lanadelumab
Speaker: Markus Magerl, Germany

Q & A - Moderator and Speakers


Satellite Symposium (SAT)
GSK
17:30 – 19:00, Hall 3
 
The Power of Long-term Data in Anti-IL-5 Choice
Chair: André Moreira, Portugal 

Welcome & Chairman's introduction
Speaker: André Moreira, Portugal 

Different MoA translates in different efficacy
Speaker: Ana Todo-Bom, Portugal 

Mepolizumab: The evidence of lasting efficacy & safety to support clinician's choice
Speaker: Emilio Pizzichini, Brazil 

Clinician's perspectives: The long-term experience with Mepolizumab
Speaker: Stefan Cimbollek, Spain 

Q & A – Close remarks
Speaker: Manuel Branco Ferreira, Portugal


Satellite Symposium (SAT)
FAES FARMA and Menarini Group
17:30 – 19:00, Hall 5
 
Bilastine: a lifetime companion - Value every moment of your life
Chair: Martin Church, United Kingdom

Patients and their Rhinitis-treatment - an on-off-Relationship
Speaker: Ralph Mösges, Germany

Unmet needs in Urticaria - Zeroing-In on the right Treatment
Speaker: Marysia Recto, The Philippines

Preserve children's daily-life activities - to be on the safe side
Speaker: Zoltán Nóvak, Hungary


Satellite Symposium (SAT)
Integritas Communications
17:30 – 19:00, Hall 7
 
Looking ahead: Optimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis
Chair: Mark Boguniewicz, United States

Introduction and Preassessment
Speaker: Mark Boguniewicz, United States

Atopic Dermatitis: Mechanistic Rationales for Advances in Therapy
Speaker: Michael Ardern-Jones, United Kingdom

Comprehensive Patient Evaluations: From Triggers to Comorbidities
Speaker: Mark Boguniewicz, United States

Long-term Management Strategies for Moderate-to-Severe Disease
Speaker: Marjolein Saskia de Bruin-Weller, Netherlands

Postactivity Questionnaire and Question & Answer Session
Speaker: Mark Boguniewicz, United States 


Monday, 3 June 2019

 

Satellite Symposium (SAT)
Laboratorios LETI
17:45 – 19:15, Hall 8
 LETIPHARMA 100 AN aOS RGB SINCE

New challenges in allergic diseases and improved technology to better control safety and efficacy of personalized immunotherapy
Chair: Torsten Zuberbier, Germany

How and why prevalence and diversity of allergies has increased and will further increase both in the next decade.
Speaker: Javier Domínguez, Spain

LETI's safety and efficacy evidence map.
Speaker: Ludger Klimek, Germany

Are we ready to take advantage of digital transformation to help allergic patients?
Speaker: Ignacio Hernández Medrano, Spain

Increasing precision of personalized allergen immunotherapy through R&D.
Speaker: Mohamed Shamji, United Kingdom



Satellite Symposium (SAT)
Sanofi Genzyme and Regeneron
17:45 – 19:15, Hall 3
SANOFI GENZYME REGENERON logo 600x200 04

A New Era in the Management of Type 2 Inflammatory Diseases: Asthma, CRSwNP, and Atopic Dermatitis — New Insights, New Treatment Options

Learning objectives:
This interactive symposium will explore how type 2 inflammation underpins multiple chronic inflammatory diseases of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis, while considering the high disease burden and unmet medical needs associated with these diseases. The latest clinical data on biologics in the treatment of type 2 inflammatory diseases of the airway and skin will be detailed, along with strategies for the use of these agents in clinical practice. Case studies will be presented throughout the symposium, alongside insight from expert panel discussions to consolidate.


Chair: William Busse, United States

Welcome and Introduction
Speaker: William Busse, United States

Commonalities across Type 2 Inflammatory Diseases in Clinical Practice
Patient Cases Presented by:
Claus Bachert, Belgium
G.Walter Canonica, Italy
Stephan Weidinger, Germany


Discussion led by:
William Busse, United States


A Closer Look at the Pathophysiologic Mechanisms Driving Multiple Type 2 Inflammatory Diseases - All Faculty

Redefining the Management of Type 2 Inflammatory Diseases of the Airways and Skin – All Faculty

Closing Remarks and Panel Q&A – All Faculty
Speaker: William Busse, United States 



Satellite Symposium (SAT)
DBV Technologies
17:45 – 19:15, Hall 10
 

What are the insights for peanut-allergic patients with Investigational EPIT?
Chair: Susanne Lau, Germany
Chair: Philippe Eigenmann, Switzerland


Leveraging the Immune Properties of the skin for an innovative approach to Food Allergy management
Speaker: Christophe Dupont, France

Adding a buffer to reduce the risk of reactions: Can efficacy meet Peace of mind? (panel discussion)
Speaker: Katharina Blümchen, Germany
Speaker: André Knulst, Netherlands
Speaker: Benjamin Remington, Netherlands 



Satellite Symposium (SAT)
CSL Behring
17:45 – 19:15, Hall 5
 

40 years of C1 inhibitor replacement therapy in the management of HAE

Learning objectives:
To highlight the 40 year legacy and history of C1 inhibitor replacement therapy and CSL Behring
To explain the mechanism of action of C1 inhibitor and the influence of C1 inhibitor replacement therapy in HAE
To describe the long-term safety and efficacy outcomes of C1 inhibitor replacement therapy using the recent data from the COMPACT open-label extension study
To detail outcomes of C1 inhibitor replacement therapy in pregnant, paediatric and geriatric patients
To emphasise the quality of life implications of HAE and how C1 inhibitor replacement therapy impacts these parameters


Chair: Konrad Bork, Germany
Chair: Werner Aberer, Austria

Patient video

Welcome and introduction
Speaker: Konrad Bork, Germany

C1 inhibitor in HAE and beyond
Speaker: Allen Kaplan, United States

Treatment outcomes in challenging patient groups with C1 inhibitor replacement therapy
Speaker: Timothy Craig, United States

C1 inhibitor replacement therapy: practical advice for patient management (RWE)
Speaker: Markus Magerl, Germany

Interactive panel discussion
Speaker: Werner Aberer, Austria 



Satellite Symposium (SAT)
Purina Institute
17:45 – 19:15, Hall 4
 

Keep the cat, change the care pathway: a transformational approach to managing cat allergy

Learning objectives:
This symposium introduces an innovative approach to reducing environmental cat allergen levels while keeping the cat in the home. With proven efficacy in reducing symptoms in sensitized individuals, this solution will reframe one of the most difficult conversations you have with patients.


Chair: Antonella Muraro, Italy

A revolution in care pathways for cat allergy
Speaker: Jean Bousquet, France

A novel method of addressing human allergies to cats
Speaker: Ebenezer Satyaraj, United States
Speaker: H. James Wedner, United States 



Satellite Symposium (SAT)
Medscape Education
17:45 – 19:15, Hall 9
 
Elevated Goals in HAE: The Impact of Targeted Therapy on Disease Management and Patient QoL
Chair: Marc A. Riedl, United States

Welcome and Introduction
Speaker: Marc A. Riedl, United States

The Changing Treatment Landscape of HAE
Speaker: Marc A. Riedl, United States

From Reactive to Preventive Therape in HAE
Speaker: Marco Cicardi, Italy

New Treatment Approaches in HAE
Speaker: Aleena Banerji, United States

Living with HAE: Implications of the Patient - Panel discussion

Audience Q&A Session - All panel members

Program Close
Speaker: Marc A. Riedl, United States

 
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel